ES2582091T3 - Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas - Google Patents

Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas Download PDF

Info

Publication number
ES2582091T3
ES2582091T3 ES13164628.3T ES13164628T ES2582091T3 ES 2582091 T3 ES2582091 T3 ES 2582091T3 ES 13164628 T ES13164628 T ES 13164628T ES 2582091 T3 ES2582091 T3 ES 2582091T3
Authority
ES
Spain
Prior art keywords
meganuclease
binding affinity
dna binding
sequence
sequence specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13164628.3T
Other languages
English (en)
Inventor
Homme W. Hellinga
James Jefferson Smith
Derek Jantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PREC BIOSCIENCES
Precision Biosciences Inc
Original Assignee
PREC BIOSCIENCES
Precision Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37963286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2582091(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PREC BIOSCIENCES, Precision Biosciences Inc filed Critical PREC BIOSCIENCES
Application granted granted Critical
Publication of ES2582091T3 publication Critical patent/ES2582091T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/905—Stable introduction of foreign DNA into chromosome using homologous recombination in yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Una meganucleasa recombinante que comprende: un polipéptido que tiene una similitud de al menos el 85 % con los restos 2-153 de la meganucleasa I-CreI de SEQ ID NO: 1; en la que la afinidad de unión a ADN se ha aumentado mediante al menos una modificación de un resto que es parte de la superficie de contacto de la estructura de la meganucleasa I-CreI de SEQ ID NO: 1, correspondiendo dicha modificación a una sustitución seleccionada entre el grupo que consiste en: sustitución de E80 por H, N, Q, S, T, K o R.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
5
15
25
35
45
55
65
reconocen específicamente pero que constituyen el sitio de escisión real (que tiene un saliente de 4 pares de bases). Por lo tanto, las secuencias de reconocimiento combinadas de los dímeros de meganucleasa I-CreI, I-MsoI e I-CeuI normalmente abarcan 22 pares de bases, incluyendo dos semi-sitios de 9 pares de bases que flanquean un sitio de escisión de 4 pares de bases. Los pares de bases de cada semi-sitio se designan de -9 a -1, siendo la posición -9 la más distal del sitio de escisión y siendo la posición -1 adyacente a los 4 pares de bases centrales, que se designan N1-N4. La hebra de cada semi-sitio que se orienta de 5' a 3' en la dirección de -9 a -1 (es decir, hacia el sitio de escisión), se designa la hebra “sentido” y la hebra opuesta se designa la “hebra antisentido”, aunque ninguna de las hebras puede codificar proteína. Por lo tanto, la hebra “sentido” de un semi-sitio es la hebra antisentido del otro semi-sitio. Véase, por ejemplo, la Figura 1 (A). En el caso de la meganucleasa I-SceI, que es un monómero de meganucleasa di-LAGLIDADG, la secuencia de reconocimiento es una secuencia no palindrómica de aproximadamente 18 pb y no hay pares de bases centrales que no se reconozcan específicamente. Por convención, una de las dos hebras se denomina la hebra “sentido” y la otra la hebra “antisentido”, aunque ninguna de las hebras puede codificar proteína.
Como se usa en el presente documento, el término “especificidad” significa la capacidad de una meganucleasa para reconocer y escindir moléculas de ADN bicatenarias solamente en una secuencia particular de pares de bases denominada secuencia de reconocimiento, o solamente en un conjunto particular de secuencias de reconocimiento. El conjunto de secuencias de reconocimiento compartirá ciertas posiciones conservadas o motivos de secuencia, pero pueden degenerarse en una o más posiciones. Una meganucleasa altamente específica es capaz de escindir solamente una o muy pocas secuencias de reconocimiento. La especificidad puede determinarse en un ensayo de escisión como se describe en el Ejemplo 1. Como se usa en el presente documento, una meganucleasa tiene especificidad “alterada” si se une a y escinde una secuencia de reconocimiento que no está unida a y escindida por una meganucleasa de referencia (por ejemplo, de tipo silvestre) o si la tasa de escisión de una secuencia de reconocimiento aumenta o se reduce por una cantidad estadísticamente significativa (p < 0,05) en relación con una meganucleasa de referencia.
Como se usa en el presente documento, el término “degeneración” significa lo opuesto de “especificidad”. Una meganucleasa altamente degenerada es capaz de escindir un gran número de secuencias de reconocimiento divergentes. Una meganucleasa puede tener degeneración de secuencia en una posición sencilla dentro de un semisitio o en múltiples, incluso todas las, posiciones dentro de un semi-sitio. Dicha degeneración de secuencia puede resultar de (i) la incapacidad de cualquier aminoácido en el dominio de unión a ADN de una meganucleasa para realizar un contacto específico con cualquier base en una o más posiciones en la secuencia de reconocimiento, (ii) la capacidad de uno o más aminoácidos en el dominio de unión a ADN de una meganucleasa para realizar un contacto específico con más de una base en una o más posiciones en la secuencia de reconocimiento y/o (iii) suficiente afinidad de unión a ADN no específico para actividad. Una posición degenerada “completamente” puede ocuparse por cualquiera de las cuatro bases y puede designarse con una “N” en un semi-sitio. Una posición degenerada “parcialmente” puede ocuparse por dos o tres de las cuatro bases (por ejemplo, purina (Pu), pirimidina (Py) o no G).
Como se usa en el presente documento con respecto a meganucleasas, la expresión “afinidad de unión a ADN” o “afinidad de unión” significa la tendencia de una meganucleasa a asociarse de forma no covalente con una molécula de ADN de referencia (por ejemplo, una secuencia de reconocimiento o una secuencia arbitraria). La afinidad de unión se mide por una constante de disociación, KD (por ejemplo, la KD de I-CreI para la secuencia de reconocimiento WT es de aproximadamente 0,1 nM). Como se usa en el presente documento, una meganucleasa tiene afinidad de unión “alterada” si la KD de la meganucleasa recombinante para una secuencia de reconocimiento de referencia aumenta o se reduce en una cantidad estadísticamente significativa (p < 0,05) en relación con una meganucleasa de referencia.
Como se usa en el presente documento con respecto a monómeros de meganucleasa, la expresión “afinidad para formación de dímeros” significa la tendencia de un monómero de meganucleasa para asociarse de forma no covalente con un monómero de meganucleasa de referencia. La afinidad para formación de dímeros puede medirse con el mismo monómero (es decir, formación de homodímeros) o con un monómero diferente (es decir, formación de heterodímeros) tal como una meganucleasa de tipo silvestre de referencia. La afinidad de unión se mide por una constante de disociación, KD. Como se usa en el presente documento, una meganucleasa tiene afinidad “alterada” para formación de dímeros si la KD del monómero de meganucleasa recombinante para un monómero de meganucleasa de referencia aumenta o se reduce en una cantidad estadísticamente significativa (p < 0,05) en relación con un monómero de meganucleasa de referencia.
Como se usa en el presente documento, el término “palindrómico” se refiere a una secuencia de reconocimiento que consiste en repeticiones invertidas de semi-sitios idénticos. En este caso, sin embargo, la secuencia palindrómica no necesita ser palindrómica con respecto a los cuatro pares de bases centrales, que no entran en contacto con la enzima. En el caso de meganucleasas diméricas, las secuencias de ADN palindrómicas se reconocen por homodímeros en los que los dos monómeros realizan contactos con semi-sitios idénticos.
Como se usa en el presente documento, la expresión “pseudo-palindrómico” se refiere a una secuencia de reconocimiento que consiste en repeticiones invertidas de semi-sitios palindrómicos no idénticos o imperfectos. En este caso, la secuencia pseudo-palindrómica no solamente no necesita ser palindrómica con respecto a los cuatro pares de base centrales, sino que también puede desviarse de una secuencia palindrómica entre los dos semi-sitios.
8
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
con un ácido glutámico en la posición 26 (véase Figura 1(D)); una A en la hebra sentido podría realizar un enlace de hidrógeno con una glutamina en la posición 77 y una T en la hebra antisentido podría formar contactos hidrófobos con una alanina en la posición 26 (véase Figura 1 (E)). Si el contacto específico de base se proporciona por la posición 77, entonces el contacto de tipo silvestre, Q26, puede sustituirse (por ejemplo, con un resto de serina) para reducir o retirar
5 su influencia en la especificidad. Como alternativa, pueden combinarse mutaciones complementarias en las posiciones 26 y 77 para especificar un par de bases particular (por ejemplo, A26 especifica una T en la hebra antisentido y Q77 especifica una A en la hebra sentido (Figura 1 (E)). Todas estas sustituciones de restos predichas se han validado experimentalmente.
10 Por lo tanto, de acuerdo con la invención, se ha identificado una variedad sustancial de modificaciones de aminoácidos para el dominio de reconocimiento de ADN de la meganucleasa I-CreI que, individualmente o en combinación, dan como resultado meganucleasas recombinantes con especificidades alteradas en bases individuales dentro del semi-sitio de secuencia de reconocimiento de ADN, de modo que estas meganucleasas diseñadas racionalmente tienen semi-sitios diferentes de la enzima de tipo silvestre. Las modificaciones de aminoácidos de I-CreI y el cambio
15 resultante en la especificidad del semi-sitio de secuencia de reconocimiento se muestran en la Tabla 1:
TABLA 1
Base de hebra sentido favorecida
Posn.
A C G T A/T A/C A/G C/T G/T A/G/T A/C/G/T
-1
Y75 L75* C75* Y139* C46* A46* R70* H75* R75* H46* K46* R46* K70 E70* E75* E46* D46* Q70* C70 L70 Y75* Q75* H75* H139 Q46* H46* T46* G70 A70 S70 G46*
-2
Q70 T44* A44* V44* I44* L44* N44* E70 D70 K44* R44* H70 D44* E44* Q44* C44*
-3
Q68 C24* I24* E68 F68 K24* R24* R68 M68 C68 L68 F68 H68 Y68 K68
-4
A26* Q77 E77 K26* R77 E26* S77 Q26* S26*
-5
E42 R42 K28* C28* Q42 M66 K66
-6
Q40 C28* E40 R28* R40 C40 I40 V40 C79 I79 V79 Q28* A40 A79 A28* H28* S40 S28*
-7
N30* Q38 E38 K30* R30* K38 R38 E30* I38 L38 C38 H38 N38 Q30*
-8
F33 Y33 E33 D33 F33 H33 L33 V33 I33 F33 C33 R32* R33
16
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28

Claims (1)

  1. imagen1
    imagen2
ES13164628.3T 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas Active ES2582091T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72751205P 2005-10-18 2005-10-18
US727512P 2005-10-18

Publications (1)

Publication Number Publication Date
ES2582091T3 true ES2582091T3 (es) 2016-09-09

Family

ID=37963286

Family Applications (9)

Application Number Title Priority Date Filing Date
ES17161899T Active ES2829549T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164585.5T Active ES2626025T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164628.3T Active ES2582091T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES12162075.1T Active ES2440801T3 (es) 2005-10-18 2006-10-18 Meganucleasas racionalmente diseñadas con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164564.0T Active ES2602184T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164623.4T Active ES2539616T3 (es) 2005-10-18 2006-10-18 Meganucleasa diseñada racionalmente con afinidad de formación de dímeros alterada
ES06826293T Active ES2425022T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191888T Active ES2384440T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191904.1T Active ES2533370T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES17161899T Active ES2829549T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164585.5T Active ES2626025T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES12162075.1T Active ES2440801T3 (es) 2005-10-18 2006-10-18 Meganucleasas racionalmente diseñadas con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164564.0T Active ES2602184T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES13164623.4T Active ES2539616T3 (es) 2005-10-18 2006-10-18 Meganucleasa diseñada racionalmente con afinidad de formación de dímeros alterada
ES06826293T Active ES2425022T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191888T Active ES2384440T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES10191904.1T Active ES2533370T3 (es) 2005-10-18 2006-10-18 Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas

Country Status (9)

Country Link
US (21) US8021867B2 (es)
EP (13) EP2341135A3 (es)
JP (10) JP5937292B2 (es)
AT (1) ATE549401T1 (es)
AU (1) AU2006304668B2 (es)
CA (3) CA2891996A1 (es)
DK (9) DK2357226T3 (es)
ES (9) ES2829549T3 (es)
WO (1) WO2007047859A2 (es)

Families Citing this family (508)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078552A1 (en) † 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20060153826A1 (en) * 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
EP2327771A1 (en) * 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
ES2465996T3 (es) * 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
AU2007347328B2 (en) * 2007-02-19 2013-03-07 Cellectis LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof
EP2160467B1 (en) 2007-06-05 2015-10-28 Bayer CropScience NV Methods and means for exact replacement of target dna in eukaryotic organisms
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
CN101849010A (zh) 2007-06-29 2010-09-29 先锋高级育种国际公司 用于改变单子叶植物细胞的基因组的方法
WO2009013559A1 (en) * 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
CA2700231C (en) * 2007-09-27 2018-09-18 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US20110014616A1 (en) * 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2215223B1 (en) * 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2009068937A1 (en) * 2007-11-28 2009-06-04 Cellectis I-msoi homing endonuclease variants having novel substrate specificity and use thereof
EP2215252A4 (en) * 2007-12-07 2011-01-26 Prec Biosciences Inc RATIONAL-DESIGNED MEGANUCLEASES WITH DETECTION SEQUENCES FROM DNASE-HYPERSENSITIVE REGIONS OF THE HUMAN GENOME
AP2967A (en) 2008-02-29 2014-09-30 Monsanto Technology Llc Zea mays plant event MON87460 and compositions andmethods for detection thereof
WO2009114321A2 (en) 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
EP2281050B1 (en) 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
EP2279250A4 (en) * 2008-04-28 2011-10-12 Prec Biosciences Inc Fusion Molecules of DNA Binding Proteins with Rational Design and Effects Domain
DK3211075T3 (en) 2008-07-14 2019-01-21 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
KR101683928B1 (ko) * 2008-12-17 2016-12-07 다우 아그로사이언시즈 엘엘씨 Ｚｐ１５ 유전자 자리 내로의 표적화 통합
JP5827132B2 (ja) 2009-02-04 2015-12-02 サンガモ バイオサイエンシズ インコーポレイテッド ニューロパチーを治療するための方法および組成物
US20110294217A1 (en) * 2009-02-12 2011-12-01 Fred Hutchinson Cancer Research Center Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion
US8871905B2 (en) 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
WO2010122367A2 (en) * 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2010136841A2 (en) * 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
US20120171191A1 (en) * 2009-05-26 2012-07-05 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
JP5866283B2 (ja) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
EP2462230B1 (en) * 2009-08-03 2015-07-15 Recombinetics, Inc. Methods and compositions for targeted gene modification
KR102262704B1 (ko) 2009-08-11 2021-06-09 상가모 테라퓨틱스, 인코포레이티드 표적화 변형에 대한 동형접합성 유기체
RU2568056C2 (ru) 2009-10-22 2015-11-10 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Конструируемые белки с цинковыми пальцами, направленные на гены растений, вовлеченные в биосинтез жирных кислот
EP2319872A1 (en) 2009-11-04 2011-05-11 BASF Plant Science GmbH Amylopectin type starch with enhanced retrogradation stability
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
EP2504439B1 (en) * 2009-11-27 2016-03-02 BASF Plant Science Company GmbH Optimized endonucleases and uses thereof
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
US8704041B2 (en) * 2009-12-30 2014-04-22 Pioneer Hi Bred International Inc Methods and compositions for targeted polynucleotide modification
US20110203012A1 (en) * 2010-01-21 2011-08-18 Dotson Stanton B Methods and compositions for use of directed recombination in plant breeding
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
AU2011219716A1 (en) * 2010-02-26 2012-09-27 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
WO2011117249A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
PT2566972T (pt) 2010-05-03 2020-03-02 Sangamo Biosciences Inc Composições para a ligação de módulos de dedo de zinco
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
US9593317B2 (en) 2010-06-09 2017-03-14 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
AU2011264075B2 (en) * 2010-06-09 2015-01-29 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
WO2012017329A2 (en) * 2010-08-02 2012-02-09 Cellectis S.A. Method for targeted genomic events in algae
CA2811364C (en) 2010-09-27 2022-01-04 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
AR084844A1 (es) 2011-01-14 2013-06-26 Jones Jeffrey B Arboles de citricos con resistencia a cancro de los citricos
MX2013010911A (es) 2011-03-23 2015-03-03 Pioneer Hi Bred Int Metodos para producir un locus de rasgo transgenico complejo.
WO2012138901A1 (en) * 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
CN103796508B (zh) 2011-05-02 2017-05-03 内布拉斯加大学评议会 具有有用性状的植物和相关方法
EP2535416A1 (en) 2011-05-24 2012-12-19 BASF Plant Science Company GmbH Development of phytophthora resistant potato with increased yield
DK2714936T3 (en) 2011-06-01 2019-03-25 Prec Biosciences Inc METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES
WO2012168124A1 (en) 2011-06-06 2012-12-13 Bayer Cropscience Nv Methods and means to modify a plant genome at a preselected site
EP2718432A4 (en) 2011-06-10 2015-01-07 Basf Plant Science Co Gmbh NUCLEASE FUSION PROTEIN AND USES THEREOF
BR112013033176A2 (pt) 2011-06-21 2018-06-12 E I Du Pont De Nemouras And Company método para produzir uma modificação direcionada em um gene de fertilidade masculina, planta, molécula de ácido nucleio isolada, construto de expressão
AR087167A1 (es) 2011-07-12 2014-02-26 Two Blades Foundation Genes de resistencia al tizon tardio
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
CN103890181A (zh) 2011-08-22 2014-06-25 拜尔作物科学公司 修饰植物基因组的方法和手段
AU2013204310C1 (en) * 2011-08-22 2015-12-10 BASF Agricultural Solutions Seed US LLC Methods and means to modify a plant genome
AU2012312260B2 (en) 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
JP6188703B2 (ja) 2011-10-27 2017-08-30 サンガモ セラピューティクス， インコーポレイテッド Ｈｐｒｔ遺伝子座を修飾するための方法および組成物
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
AU2013209738A1 (en) 2012-01-17 2014-08-07 Australian Center For Plant Functional Genomics, Pty, Ltd Plant transcription factors, promoters and uses thereof
BR112014018294B1 (pt) 2012-01-26 2022-01-11 Norfolk Plant Sciences, Ltd Método para produzir uma planta, cassete de expressão, e, célula bacteriana
CN108285491B (zh) 2012-02-29 2021-08-10 桑格摩生物科学股份有限公司 治疗亨廷顿氏病的方法和组合物
CN104302773A (zh) 2012-03-13 2015-01-21 圭尔夫大学 增加植物对热胁迫的耐受性及氨基酸含量的方法
US20150203864A1 (en) 2012-03-13 2015-07-23 University Of Guelph Myb55 promoter and use thereof
AU2013254857B2 (en) 2012-04-23 2018-04-26 Bayer Cropscience Nv Targeted genome engineering in plants
CA2872124C (en) 2012-05-02 2022-05-03 Dow Agrosciences Llc Plant with targeted modification of the endogenous malate dehydrogenase gene
BR112014027468A2 (pt) 2012-05-04 2017-06-27 Du Pont polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo.
AU2013259647B2 (en) 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
DK3444342T3 (da) 2012-07-11 2020-08-24 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
SI2890780T1 (sl) 2012-08-29 2020-11-30 Sangamo Therapeutics, Inc. Postopki in sestavki za zdravljenje genetskega stanja
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
SG11201504038XA (en) 2012-11-27 2015-06-29 Childrens Medical Center Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
CA2895117A1 (en) 2012-12-13 2014-06-19 James W. Bing Precision gene targeting to a particular locus in maize
US10227610B2 (en) * 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
EP2981614A1 (en) 2013-04-02 2016-02-10 Bayer CropScience NV Targeted genome engineering in eukaryotes
EP2981166B1 (en) 2013-04-05 2020-09-09 Dow AgroSciences LLC Methods and compositions for integration of an exogenous sequence within the genome of plants
EP3019005B1 (en) 2013-07-10 2019-02-20 EffStock, LLC Mrap2 knockouts
CA3109801C (en) 2013-08-22 2024-01-09 Andrew Cigan Plant genome modification using guide rna/cas endonuclease systems and methods of use
AU2014312295C1 (en) 2013-08-28 2020-08-13 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US10767188B2 (en) 2013-09-25 2020-09-08 Nutech Ventures Methods and compositions for obtaining useful plant traits
KR20150037550A (ko) * 2013-09-30 2015-04-08 주식회사 엘지화학 국지적으로 편광 해소 영역을 갖는 편광판 및 그 제조 방법
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
CN105899665B (zh) 2013-10-17 2019-10-22 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
KR102269371B1 (ko) 2013-11-04 2021-06-28 코르테바 애그리사이언스 엘엘씨 최적 메이즈 유전자좌
KR102269769B1 (ko) 2013-11-04 2021-06-28 코르테바 애그리사이언스 엘엘씨 최적 메이즈 유전자좌
MX358066B (es) 2013-11-04 2018-08-03 Dow Agrosciences Llc Óptimos loci de soya.
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
HUE044540T2 (hu) 2013-11-13 2019-10-28 Childrens Medical Center Nukleáz közvetítette génexpresszió-szabályozás
DK3080274T3 (da) 2013-12-09 2020-08-31 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til genom-manipulation
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
WO2015116680A1 (en) 2014-01-30 2015-08-06 Two Blades Foundation Plants with enhanced resistance to phytophthora
WO2015117081A2 (en) 2014-02-03 2015-08-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a beta thalessemia
AU2015218576B2 (en) 2014-02-24 2020-02-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
CA2942268A1 (en) 2014-03-12 2015-09-17 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
CN106459894B (zh) 2014-03-18 2020-02-18 桑格摩生物科学股份有限公司 用于调控锌指蛋白表达的方法和组合物
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
RU2691102C2 (ru) 2014-05-08 2019-06-11 Сангамо Байосайенсиз, Инк. Способы и композиции для лечения болезни хантингтона
DE102014209264B8 (de) * 2014-05-15 2017-01-12 Olympus Winter & Ibe Gmbh Hochfrequenz-Chirurgiegerät
EP3149171A1 (en) * 2014-05-30 2017-04-05 The Board of Trustees of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
AU2015288157A1 (en) 2014-07-11 2017-01-19 E. I. Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
HUE055583T2 (hu) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
WO2016054326A1 (en) 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
WO2016100333A1 (en) 2014-12-15 2016-06-23 Syngenta Participations Ag Pesticidal microrna carriers and use thereof
CA2969151A1 (en) 2014-12-23 2016-06-30 Syngenta Participations Ag Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
WO2016157175A1 (en) 2015-03-27 2016-10-06 Yeda Research And Development Co. Ltd. Methods of treating motor neuron diseases
AU2016243052C1 (en) 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
CA2982927C (en) 2015-04-15 2023-08-29 Dow Agrosciences Llc Plant promoter for transgene expression
BR112017021703B1 (pt) 2015-04-15 2023-11-28 Corteva Agriscience Llc Promotor de planta para expressão de transgene
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US20180344817A1 (en) 2015-05-01 2018-12-06 Precision Biosciences, Inc. Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
ES2835861T5 (en) 2015-05-08 2025-02-18 Childrens Medical Ct Corp Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
CN107709564B (zh) 2015-05-09 2021-11-02 双刃基金会 来自少花龙葵的抗晚疫病基因及使用方法
EP3294280A1 (en) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrin inhibitors for the treatment of cancer
EP3294773A1 (en) 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
WO2016205825A1 (en) 2015-06-19 2016-12-22 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3322297B1 (en) 2015-07-13 2024-12-04 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10882894B2 (en) 2015-08-11 2021-01-05 Anie Philip Peptidic TGF-beta antagonists
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US10603363B2 (en) * 2015-09-08 2020-03-31 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
TW201718862A (zh) 2015-09-22 2017-06-01 Dow Agrosciences Llc 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
TW201718861A (zh) 2015-09-22 2017-06-01 道禮責任有限公司 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
CN117070468A (zh) 2015-10-05 2023-11-17 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
AU2016340893B2 (en) 2015-10-22 2019-06-27 Corteva Agriscience Llc Plant promoter for transgene expression
MX2018005274A (es) 2015-10-30 2019-09-19 The Regents Of The Universtiy Of California Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
WO2017078935A1 (en) 2015-11-04 2017-05-11 Dow Agrosciences Llc Plant promoter for transgene expression
AU2016349738A1 (en) 2015-11-06 2018-05-24 The Jackson Laboratory Large genomic DNA knock-in and uses thereof
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
IL297018A (en) 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Directed cleavage of cell mhc receptor
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
EP3988655A3 (en) 2015-12-23 2022-08-03 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
JP2019505511A (ja) 2016-01-06 2019-02-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法
ES2875747T3 (es) 2016-01-11 2021-11-11 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia
WO2017123559A2 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
CN109068605B (zh) 2016-01-21 2022-11-11 以色列国家农业和农村发展农业研究组织沃尔坎尼中心 单性结实植物及其产生方法
WO2017130205A1 (en) 2016-01-31 2017-08-03 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
EP3411056A4 (en) 2016-02-02 2019-10-02 Sangamo Therapeutics, Inc. COMPOUNDS FOR NETWORKING DNA BINDING DOMAINS AND SPLITTING DOMAINS
WO2017138008A2 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
CN109069870B (zh) 2016-02-24 2022-04-29 洛克菲勒大学 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选系统、模型及它们的应用
US20190216891A1 (en) 2016-03-06 2019-07-18 Yeda Research And Development Co., Ltd. Method for modulating myelination
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017189893A1 (en) 2016-04-27 2017-11-02 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
DK3452583T3 (da) 2016-05-03 2022-01-10 Prec Biosciences Inc Konstruerede nukleaser, der er nyttige til behandling af hæmofili a
CA3021682A1 (en) 2016-05-25 2017-11-30 Cargill Incorporated Engineered nucleases to generate deletion mutants in plants
BR112018074101A2 (pt) 2016-05-26 2019-03-06 Nunhems Bv plantas produtoras de fruto sem semente
WO2017221225A1 (en) 2016-06-19 2017-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Screening for chemotherapy resistance in human haploid cells
BR112018076811A2 (pt) 2016-06-22 2019-08-27 Univ North Carolina State métodos, usos, construção ou vetor, célula, planta, material de propagação de planta, folha colhida, folha processada, produto de planta, produto de tabaco, extrato de planta e artigo de fumar
KR20190031306A (ko) 2016-07-21 2019-03-25 맥스시티 인코포레이티드 게놈 dna를 변경하기 위한 방법 및 조성물
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
CA3035075A1 (en) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US10400246B2 (en) 2016-10-03 2019-09-03 Dow Agrosciences Llc Plant promoter for transgene expression
US10519459B2 (en) 2016-10-03 2019-12-31 Dow Agrosciences Llc Plant promoter from Panicum virgatum
ES2925644T3 (es) 2016-10-04 2022-10-19 Prec Biosciences Inc Dominios coestimuladores para su uso en células modificadas genéticamente
IL265921B2 (en) 2016-10-14 2024-05-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
CA3039673A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
JP7108608B2 (ja) 2016-10-31 2022-07-28 サンガモ セラピューティクス， インコーポレイテッド 造血幹細胞および前駆細胞におけるｓｃｉｄ関連遺伝子の遺伝子修正
WO2018076335A1 (en) 2016-10-31 2018-05-03 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Compositions and methods for enhancing abiotic stress tolerance
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
JP7416406B2 (ja) 2016-12-08 2024-01-17 ケース ウェスタン リザーブ ユニバーシティ 機能的ミエリン産生を増進させるための方法および組成物
EP3563159A1 (en) 2016-12-29 2019-11-06 Ukko Inc. Methods for identifying and de-epitoping allergenic polypeptides
MX2019010972A (es) 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
US12161694B2 (en) 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
MX392743B (es) 2017-04-12 2025-03-12 Magenta Therapeutics Inc Antagonistas del receptor de hidrocarburo de arilo y sus usos.
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018191558A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
US12331319B2 (en) 2017-04-12 2025-06-17 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
EP3612205B9 (en) 2017-04-21 2023-10-04 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the pcsk9 gene
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018201144A1 (en) 2017-04-28 2018-11-01 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
JP2020518245A (ja) 2017-05-03 2020-06-25 サンガモ セラピューティクス， インコーポレイテッド 嚢胞性線維症膜貫通コンダクタンス制御因子（ｃｆｔｒ）遺伝子の改変のための方法および組成物
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
EP4029943A1 (en) 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
EP3630973A1 (en) 2017-05-31 2020-04-08 Tropic Biosciences UK Limited Methods of selecting cells comprising genome editing events
GB201708665D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing extractability of solids from coffee beans
GB201708662D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing shelf-life of banana
WO2018224861A1 (en) 2017-06-07 2018-12-13 International Rice Research Institute Increasing hybrid seed production through higher outcrossing rate in cytoplasmic male sterile gramineae plants and related materials and methods
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
CN111315891A (zh) 2017-06-23 2020-06-19 肯塔基大学研究基金会 方法
AU2018290843B2 (en) 2017-06-26 2025-04-24 Massachusetts Institute Of Technology CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
EP3654763A4 (en) 2017-06-28 2021-06-09 Dow Agrosciences LLC PLANT PROMOTER FOR TRANSGENIC EXPRESSION
CA3068465A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
EP3654993A4 (en) 2017-07-17 2021-08-25 The Broad Institute, Inc. CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
AR112465A1 (es) 2017-07-31 2019-10-30 Reynolds Tobacco Co R Métodos y composiciones para la edición de genes de base viral en plantas
US10430138B2 (en) * 2017-08-10 2019-10-01 Canon Kabushiki Kaisha Communication apparatus
KR20200035104A (ko) 2017-08-11 2020-04-01 프레드 헛친슨 켄서 리서치 센터 Braf 특이적 tcr 및 그의 용도
US11692166B2 (en) 2017-08-23 2023-07-04 Technion Research & Development Foundation Limited Compositions and methods for improving alcohol tolerance in yeast
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
JP7407701B2 (ja) 2017-09-06 2024-01-04 フレッド ハッチンソン キャンサー センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
WO2019058376A1 (en) 2017-09-19 2019-03-28 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) BIRDS WITH GENOME EDITION
US20200270604A1 (en) 2017-09-19 2020-08-27 Tropic Biosciences UK Limited Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
EP3692152B1 (en) 2017-10-04 2025-09-03 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3697435A1 (en) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
CN111565731B (zh) 2017-10-24 2024-03-08 达莉亚·伊兰妮 治疗缺血性疾病的方法
CN111295093B (zh) 2017-10-30 2024-06-11 美国陶氏益农公司 用于转基因表达的植物启动子
WO2019089833A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
US20200299658A1 (en) 2017-11-01 2020-09-24 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
EP3706766A4 (en) 2017-11-09 2021-08-18 Sangamo Therapeutics, Inc. GENETIC MODIFICATION OF THE CYTOCINE INDUCTIBLE SH2-CONTAINING PROTEIN (CISH) GENE
WO2019094984A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
EP3707642A1 (en) 2017-12-03 2020-09-16 Seedx Technologies Inc. Systems and methods for sorting of seeds
US11504748B2 (en) 2017-12-03 2022-11-22 Seedx Technologies Inc. Systems and methods for sorting of seeds
EP3707641A2 (en) 2017-12-03 2020-09-16 Seedx Technologies Inc. Systems and methods for sorting of seeds
CN111712262A (zh) 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
EP3735412B1 (en) 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
CA3086620A1 (en) 2018-01-12 2019-07-18 Basf Se Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
EP3737226A1 (en) 2018-01-12 2020-11-18 Two Blades Foundation Stem rust resistance genes and methods of use
EP3749368A1 (en) 2018-02-08 2020-12-16 Yeda Research and Development Co. Ltd Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
US20210079061A1 (en) 2018-02-26 2021-03-18 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
CN111936617A (zh) 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
IT201800004253A1 (it) 2018-04-05 2019-10-05 Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3095795A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
US20210163937A1 (en) 2018-04-18 2021-06-03 B.R.A.I.N. Biotechnology Research And Information Network Ag Enrichment of genome-edited cells
DK3560330T3 (da) 2018-04-24 2022-07-11 Kws Saat Se & Co Kgaa Planter med forbedret fordøjelighed og markørhaplotyper
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
GB201807192D0 (en) 2018-05-01 2018-06-13 Tropic Biosciences Uk Ltd Compositions and methods for reducing caffeine content in coffee beans
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US20210238312A1 (en) 2018-06-13 2021-08-05 The Children's Medical Center Corporation Methods and compositions relating to high-throughput models for antibody discovery and/or optimization
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US11291176B2 (en) 2018-06-15 2022-04-05 Nunhems B.V. Seedless watermelon plants comprising modifications in an ABC transporter gene
WO2020003311A1 (en) 2018-06-25 2020-01-02 Yeda Research And Development Co. Ltd. Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en) 2018-07-04 2020-01-09 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
CN112823011A (zh) 2018-07-09 2021-05-18 加利福尼亚大学董事会 基于t细胞的免疫疗法的基因靶标
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
GB201812603D0 (en) 2018-08-02 2018-09-19 British American Tobacco Investments Ltd Method
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
MX2021001938A (es) 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.
BR112021003830A2 (pt) 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
EP3847159A2 (en) 2018-09-04 2021-07-14 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
WO2020061161A1 (en) 2018-09-18 2020-03-26 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
KR20210070344A (ko) 2018-10-02 2021-06-14 상가모 테라퓨틱스, 인코포레이티드 타우 단백질의 조정을 위한 방법 및 조성물
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
JP7543259B2 (ja) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
US12402610B2 (en) 2018-11-09 2025-09-02 The Broad Institute, Inc. Methods and compositions for modulating innate lymphoid cell pathogenic effectors
KR20210102231A (ko) 2018-11-09 2021-08-19 프레드 헛친슨 켄서 리서치 센터 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
US12165743B2 (en) 2018-11-09 2024-12-10 The Broad Institute, Inc. Compressed sensing for screening and tissue imaging
GB201818715D0 (en) 2018-11-16 2019-01-02 British American Tobacco Investments Ltd Method
CA3124110A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US20220090047A1 (en) 2018-12-21 2022-03-24 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
US12173299B2 (en) 2019-01-04 2024-12-24 Pioneer Hi-Bred International, Inc. Engineered nucleases to generate mutations in plants
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
MY202837A (en) 2019-01-11 2024-05-24 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active agents
GB201900940D0 (en) 2019-01-23 2019-03-13 British American Tobacco Investments Ltd Method
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
US20230053540A1 (en) 2019-02-19 2023-02-23 Massachusetts Institute Of Technology Treatment of liver injury
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
EP3927378A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
IL286011B2 (en) 2019-03-05 2024-06-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Genome-edited birds
CN113784978B (zh) 2019-03-11 2025-07-25 弗雷德哈钦森癌症中心 高亲合力wt1 t细胞受体及其用途
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US12419915B2 (en) 2019-03-13 2025-09-23 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
WO2020186235A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
US20220142948A1 (en) 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
JP2022519949A (ja) 2019-04-02 2022-03-25 サンガモ セラピューティクス， インコーポレイテッド ベータ－サラセミアの治療のための方法
JP7286796B2 (ja) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ，インク． マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
MX2021012836A (es) 2019-04-23 2021-12-10 Sangamo Therapeutics Inc Moduladores de la expresion del gen del marco de lectura abierto 72 del cromosoma 9 y usos de los mismos.
CA3137975A1 (en) 2019-05-07 2020-11-12 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
US20220243287A1 (en) 2019-05-13 2022-08-04 KWS SAAT SE & Co. KGaA Drought tolerance in corn
US20220249701A1 (en) 2019-05-14 2022-08-11 The Broad Institute, Inc. Compositions and methods for targeting multinucleated cells
GB201906768D0 (en) 2019-05-14 2019-06-26 British American Tobacco Investments Ltd Method
AR118995A1 (es) 2019-05-25 2021-11-17 Kws Saat Se & Co Kgaa Mejorador de la inducción de haploides
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112021026248A2 (pt) 2019-06-27 2022-03-03 Two Blades Found Molécula de ácido nucleico isolada que codifica uma proteína atrlp23 engenheirada, proteína atrlp23 engenheirada, cassete de expressão, vetor, célula hospedeira, planta ou célula vegetal, métodos para fazer uma proteína atrlp23 engenheirada, para fazer uma molécula de ácido nucleico que codifica uma proteína atrlp23 engenheirada e para intensificar a resistência de uma planta
GB201909563D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
GB201909562D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
KR20220042139A (ko) 2019-07-04 2022-04-04 유코 아이엔씨. 에피토프 제거된 알파 글리아딘 및 복강병 및 글루텐 민감성의 관리를 위한 이의 용도
WO2021011348A1 (en) 2019-07-12 2021-01-21 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
EP3999091A1 (en) 2019-07-15 2022-05-25 MedImmune Limited Tripartite systems for protein dimerization and methods of use
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
US20220298522A1 (en) 2019-07-30 2022-09-22 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
AU2020322021A1 (en) 2019-07-30 2022-02-10 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
JP2022543112A (ja) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド Ｄｕｘ４発現細胞およびそれらの使用
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021067864A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
KR20220071248A (ko) 2019-10-02 2022-05-31 상가모 테라퓨틱스, 인코포레이티드 알파-시누클레인 발현을 억제시키기 위한 아연 핑거 단백질 전사 인자
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US20230357788A1 (en) 2019-10-17 2023-11-09 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US12385054B2 (en) 2019-11-19 2025-08-12 Protalix Ltd. Removal of constructs from transformed cells
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP4069285A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
US12241830B2 (en) 2019-12-06 2025-03-04 Broad Institute, Inc. Living biosensors
EP3835309A1 (en) 2019-12-13 2021-06-16 KWS SAAT SE & Co. KGaA Method for increasing cold or frost tolerance in a plant
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev System and methods for identifying cells that have undergone genome editing
WO2021133793A1 (en) 2019-12-26 2021-07-01 Figene, Llc Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
MX2022011831A (es) 2020-03-25 2023-01-04 Sana Biotechnology Inc Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
WO2021202513A1 (en) 2020-03-31 2021-10-07 Elo Life Systems Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
BR112022020546A2 (pt) 2020-04-09 2022-12-20 Reynolds Tobacco Co R Método
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
US20230212613A1 (en) 2020-05-06 2023-07-06 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
EP4146284A1 (en) 2020-05-06 2023-03-15 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
US12595469B2 (en) 2020-05-12 2026-04-07 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
US20230304034A1 (en) 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
PE20230080A1 (es) 2020-05-29 2023-01-11 Kws Saat Se And Co Kgaa Induccion de haploides en plantas
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
US20230309480A1 (en) 2020-08-18 2023-10-05 International Rice Research Institute Methods of increasing outcrossing rates in gramineae
AU2021329403A1 (en) 2020-08-21 2023-05-04 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
US12152251B2 (en) 2020-08-25 2024-11-26 Kite Pharma, Inc. T cells with improved functionality
US20250018036A1 (en) 2020-09-24 2025-01-16 Fred Hutchinson Cancer Center Immunotherapy targeting sox2 antigens
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
KR20230074519A (ko) 2020-09-25 2023-05-30 상가모 테라퓨틱스, 인코포레이티드 핵염기 편집을 위한 아연 핑거 융합 단백질
EP4225902A1 (en) 2020-10-05 2023-08-16 Protalix Ltd. Dicer-like knock-out plant cells
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
US20240060079A1 (en) 2020-10-23 2024-02-22 Elo Life Systems Methods for producing vanilla plants with improved flavor and agronomic production
AU2021369793A1 (en) 2020-10-29 2023-06-08 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
CA3172481A1 (en) 2020-11-12 2022-05-19 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
AU2021387979A1 (en) 2020-11-26 2023-03-30 Ukko Inc. Modified high molecular weight glutenin subunit and uses thereof
CA3201767A1 (en) 2020-12-14 2022-06-23 Thomas M. Schmitt Compositions and methods for cellular immunotherapy
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
WO2022150616A1 (en) 2021-01-08 2022-07-14 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
AU2022218866A1 (en) 2021-02-09 2023-08-24 The Regents Of The University Of California Immune regulators involved in defense against plant diseases caused by liberibacter species
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
EP4326862A1 (en) 2021-04-22 2024-02-28 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
WO2022226316A1 (en) 2021-04-22 2022-10-27 Precision Biosciences, Inc. Compositions and methods for generating male sterile plants
CA3173245A1 (en) 2021-04-22 2022-10-22 James Jefferson Smith Engineered meganucleases that target human mitochondrial genomes
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
AU2022272489A1 (en) 2021-05-10 2023-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions for treating neurological conditions
BR112023023667A2 (pt) 2021-05-11 2024-01-30 Two Blades Found Métodos para preparar uma biblioteca de genes de resistência à doença de planta e à praga de planta, para identificar um gene de resistência à doença de planta e à praga de planta, para produzir uma planta com resistência aprimorada a uma doença de planta e para limitar uma doença de planta na produção de safras agrícolas, biblioteca de genes de resistência candidatos, planta transgênica, coleção de plantas transgênicas, planta ou célula de planta resistente compreendendo um gene de resistência, gene de resistência isolado, célula hospedeira, molécula de ácido nucleico, cassete de expressão, vetor, planta de trigo, semente de trigo ou célula de trigo, planta ou semente transgênica, planta, semente da planta, uso da planta ou semente, produto alimentício humano ou animal, e, polipeptídeo
WO2022242644A1 (zh) 2021-05-18 2022-11-24 赛斯尔擎生物技术（上海）有限公司 修饰细胞的方法
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
EP4362662A1 (en) 2021-07-02 2024-05-08 Tropic Biosciences UK Limited Delay or prevention of browning in banana fruit
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
AR126622A1 (es) 2021-07-30 2023-10-25 Kws Saat Se & Co Kgaa Plantas con digestibilidad mejorada y haplotipos marcadores
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
EP4384603A1 (en) 2021-08-10 2024-06-19 Gamida-Cell Ltd. Engineered nk cells, methods of their production and uses thereof
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
TW202321435A (zh) 2021-08-11 2023-06-01 美商薩那生物科技公司 用於改變低免疫原性細胞中之基因表現之可誘導系統
KR20240073006A (ko) 2021-08-11 2024-05-24 사나 바이오테크놀로지, 인크. 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
GB202112866D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to fusarium wilt in a banana
GB202112865D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to black sigatoka disease in banana
AU2022356378A1 (en) 2021-09-30 2024-05-02 Two Blades Foundation Plant disease resistance genes against stem rust and methods of use
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
EP4419111A1 (en) 2021-10-19 2024-08-28 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
MX2024004840A (es) 2021-10-19 2024-07-09 Prec Biosciences Inc Método de edición de genes para tratar la deficiencia de alfa-1 antitripsina (aat).
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
EP4430206A1 (en) 2021-11-10 2024-09-18 Encodia, Inc. Methods for barcoding macromolecules in individual cells
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4437092A1 (en) 2021-11-26 2024-10-02 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
IL313518A (en) 2021-12-17 2024-08-01 Tropic Biosciences Uk Ltd Agrobacteria adapted for gene editing in plants
CN118591626A (zh) 2021-12-22 2024-09-03 桑格摩生物治疗股份有限公司 用于核碱基编辑的新型锌指融合蛋白
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
EP4460334A1 (en) 2022-01-07 2024-11-13 Precision BioSciences, Inc. Optimized polynucleotides for protein expression
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250215443A1 (en) 2022-02-03 2025-07-03 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
WO2023148476A1 (en) 2022-02-03 2023-08-10 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
JP2025505606A (ja) 2022-02-04 2025-02-28 ニコベンチャーズ トレーディング リミテッド タバコ植物のアルカロイド含有量を調節する方法
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
EP4482500A1 (en) 2022-02-22 2025-01-01 Ecole Polytechnique Federale De Lausanne (Epfl) Cgas super-enzymes for cancer immunotherapy
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
CN119562762A (zh) 2022-04-04 2025-03-04 加利福尼亚大学董事会 遗传互补组合物和方法
GB202205149D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205148D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205562D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202205561D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202206107D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
GB202206109D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4522210A1 (en) 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvovirus with a modified genome for gene therapy
WO2023220040A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus with a modified capsid for gene therapy
EP4522201A1 (en) 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvovirus compositions and methods for gene therapy
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
EP4278891A1 (en) 2022-05-20 2023-11-22 KWS SAAT SE & Co. KGaA Clubroot resistance and markers in brassica
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
CN120019150A (zh) 2022-08-16 2025-05-16 赛斯尔擎生物技术（上海）有限公司 工程化免疫细胞及其制备方法
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250386788A1 (en) 2022-08-26 2025-12-25 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding
WO2024056902A2 (en) 2022-09-16 2024-03-21 Christopher Shaw Compositions and methods for treating neurological diseases
WO2024079157A1 (en) 2022-10-11 2024-04-18 KWS SAAT SE & Co. KGaA Virus and insect resistance and markers in barley
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
CN120239706A (zh) 2022-11-07 2025-07-01 先正达农作物保护股份公司 改变大豆植物开花时间和/或成熟的基因及其用途
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
AU2023392154A1 (en) 2022-12-14 2025-06-26 King's College London Compositions and methods for treating neurological diseases
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
GB202300905D0 (en) 2023-01-20 2023-03-08 Nicoventures Trading Ltd Method
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases
EP4662320A1 (en) 2023-02-06 2025-12-17 Bluerock Therapeutics LP Degron fusion proteins and methods of production and use thereof
GB202303077D0 (en) 2023-03-02 2023-04-19 Univ Oslo Brassica plants with improved seed retention
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
US12383615B2 (en) 2023-03-23 2025-08-12 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
GB202305021D0 (en) 2023-04-04 2023-05-17 Tropic Biosciences Uk Ltd Methods for generating breaks in a genome
KR20260010765A (ko) 2023-04-14 2026-01-21 프리시젼 바이오사이언시스 인코포레이티드 근육-특이적 발현 카세트
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
EP4477069A1 (en) 2023-06-16 2024-12-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Unreduced clonal gamete formation and polyploid genome design in the solanaceae
WO2024261102A1 (en) 2023-06-22 2024-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) The crl5spsb3 ubiquitin ligase targets nuclear cgas for degradation
CN121752717A (zh) 2023-06-23 2026-03-27 阿斯利康(瑞典)有限公司 分子开关
WO2025004001A1 (en) 2023-06-30 2025-01-02 Takeda Pharmaceutical Company Limited Htt repressors and uses thereof
WO2025019221A1 (en) 2023-07-15 2025-01-23 Two Blades Foundation Broad-spectrum polerovirus resistance gene
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025059215A1 (en) 2023-09-12 2025-03-20 Aadigen, Llc Methods and compositions for treating or preventing cancer
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025083169A1 (en) 2023-10-17 2025-04-24 Tenpoint Therapeutics Limited Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
WO2025101946A1 (en) 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025126153A2 (en) 2023-12-14 2025-06-19 Aviadobio Ltd. Compositions and methods for treating sod1-mediated neurological diseases
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof
WO2026028165A1 (en) 2024-08-01 2026-02-05 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the c9orf72 gene
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
WO2026078579A1 (en) 2024-10-08 2026-04-16 Precision Biosciences, Inc. Methods and compositions for treating hepatitis b virus-related conditions

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6265196B1 (en) 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
WO2000046386A2 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
JP2002535994A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 標的ｄｎａのインビボ除去による遺伝子修復
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US6988041B2 (en) 2000-01-31 2006-01-17 Pharmacia & Upjohn Company Crystallization and structure determination of Staphylococcus aureus NAD synthetase
DE10131786A1 (de) 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
EP1421187B1 (en) 2001-07-27 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Systems for in vivo site-directed mutagenesis using oligonucleotides
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
DE10226316B4 (de) * 2002-06-10 2004-10-28 Siemens Ag Verfahren zum Einrichten eines Zusatzdientes in einem Mobilfunknetz
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7285699B2 (en) 2002-10-07 2007-10-23 Stowers Institute For Medical Research Ends-out gene targeting method
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4885727B2 (ja) 2003-11-18 2012-02-29 バイエル・バイオサイエンス・エヌ・ヴェー 植物における改善された標的に向けたｄｎａ挿入
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
WO2007034262A1 (en) 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
EP2327771A1 (en) 2005-03-15 2011-06-01 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof

Also Published As

Publication number Publication date
US8377674B2 (en) 2013-02-19
DK3246403T3 (da) 2020-10-26
US20120021520A1 (en) 2012-01-26
US20120021521A1 (en) 2012-01-26
EP2368981A2 (en) 2011-09-28
ES2829549T3 (es) 2021-06-01
JP2025176009A (ja) 2025-12-03
EP2628794B1 (en) 2016-05-04
EP3246403A3 (en) 2018-02-14
US20120015406A1 (en) 2012-01-19
JP2022070928A (ja) 2022-05-13
US20200109383A1 (en) 2020-04-09
DK2650366T3 (en) 2017-07-10
EP2368981A3 (en) 2011-10-12
DK2484758T3 (da) 2014-01-06
EP2341135A3 (en) 2011-10-12
EP2360244A1 (en) 2011-08-24
JP2009511085A (ja) 2009-03-19
EP3246403B1 (en) 2020-08-26
US8143016B2 (en) 2012-03-27
EP2357226A1 (en) 2011-08-17
ES2539616T3 (es) 2015-07-02
JP2021054830A (ja) 2021-04-08
US20120040406A1 (en) 2012-02-16
CA3055968A1 (en) 2007-04-26
DK2650365T3 (en) 2016-12-05
ES2626025T3 (es) 2017-07-21
US20150135345A1 (en) 2015-05-14
WO2007047859A2 (en) 2007-04-26
US20120264189A1 (en) 2012-10-18
EP1945762B1 (en) 2013-05-01
ES2533370T3 (es) 2015-04-09
ATE549401T1 (de) 2012-03-15
US8304222B1 (en) 2012-11-06
JP2018039808A (ja) 2018-03-15
US20170335299A1 (en) 2017-11-23
EP2650366A3 (en) 2014-02-12
US8124369B2 (en) 2012-02-28
US20210284980A1 (en) 2021-09-16
EP2662442B1 (en) 2015-03-25
EP2484758A1 (en) 2012-08-08
EP2327774A2 (en) 2011-06-01
EP2628794A3 (en) 2013-12-04
AU2006304668A1 (en) 2007-04-26
EP2360244B1 (en) 2014-12-24
US20120021465A1 (en) 2012-01-26
JP2019077698A (ja) 2019-05-23
EP2341135A2 (en) 2011-07-06
JP6148437B2 (ja) 2017-06-14
CA2626262A1 (en) 2007-04-26
EP2662442A1 (en) 2013-11-13
EP2484758B1 (en) 2013-10-02
EP2628794A2 (en) 2013-08-21
EP3246403A2 (en) 2017-11-22
JP2013034473A (ja) 2013-02-21
JP5937292B2 (ja) 2016-06-22
US20250388884A1 (en) 2025-12-25
US20070117128A1 (en) 2007-05-24
US8119361B2 (en) 2012-02-21
ES2602184T3 (es) 2017-02-20
US8129134B2 (en) 2012-03-06
US20240228994A9 (en) 2024-07-11
EP1945762A2 (en) 2008-07-23
US20120015421A1 (en) 2012-01-19
US20120028315A1 (en) 2012-02-02
US8133697B2 (en) 2012-03-13
US20120030783A1 (en) 2012-02-02
US8148098B2 (en) 2012-04-03
ES2384440T3 (es) 2012-07-04
ES2440801T3 (es) 2014-01-30
EP2650366B1 (en) 2017-03-22
US20130227720A1 (en) 2013-08-29
US20240132862A1 (en) 2024-04-25
WO2007047859A3 (en) 2007-11-15
CA2626262C (en) 2015-09-08
US20120028314A1 (en) 2012-02-02
JP2017048179A (ja) 2017-03-09
ES2425022T3 (es) 2013-10-10
US8021867B2 (en) 2011-09-20
EP2327774A3 (en) 2011-09-28
DK2628794T3 (en) 2016-08-15
EP2357226B1 (en) 2012-03-14
EP3795682A2 (en) 2021-03-24
EP2650365A1 (en) 2013-10-16
DK1945762T3 (da) 2013-07-29
US8143015B2 (en) 2012-03-27
JP2024001024A (ja) 2024-01-09
EP2650365B1 (en) 2016-09-14
EP3795682A3 (en) 2021-06-16
US8163514B2 (en) 2012-04-24
DK2662442T3 (en) 2015-07-06
US20120266266A1 (en) 2012-10-18
CA2891996A1 (en) 2007-04-26
US20120040405A1 (en) 2012-02-16
DK2357226T3 (da) 2012-06-25
AU2006304668B2 (en) 2013-03-07
EP2650366A2 (en) 2013-10-16
JP6050611B2 (ja) 2016-12-21
JP2012196214A (ja) 2012-10-18
DK2360244T3 (en) 2015-04-07
US20120070877A1 (en) 2012-03-22
US8119381B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
ES2582091T3 (es) Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES2575412T3 (es) Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
JP2017051190A5 (es)
ES2625941T3 (es) Secuencias de reconocimiento para meganucleasas derivadas de i-crei y sus usos
BR112022008415A2 (pt) Composições e métodos para substituição do dna codificado pelo rna dos alelos
ES2906059T3 (es) Endonucleasas de acoplamiento con enzimas de procesamiento de extremos que impulsan la interrupción génica de alta eficiencia
JP2022124487A (ja) 遺伝子編集のための進化したＣａｓ９蛋白質
CA3166153A1 (en) Base editors, compositions, and methods for modifying the mitochondrial genome
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
JP7840266B2 (ja) 生化学反応方法及び天然変性領域を含む試薬
Shiura et al. PEG10 viral aspartic protease domain is essential for the maintenance of fetal capillary structure in the mouse placenta
JP2016537008A (ja) Ｃａｓ９バリアントおよびその使用
AR046089A1 (es) Plantas con actividad restringida de una enzima de ramificacion de la clase 3
DE212017000061U1 (de) Zusammensetzung zum Nachweis einer einzelsträngigen Target-RNA
WO2006037484A3 (de) Alpha-amylase-varianten mit erhöhter lösungsmittelstabilität, verfahren zu deren herstellung sowie wasch- und reinigungsmittel mit diesen alpha-amylase-varianten
ES2387546T3 (es) Péptidos y moléculas relacionadas que se unen a TALL-1
CN105658794A (zh) 核酸酶概况分析系统
CO2025005052A2 (es) Composiciones de arnip y métodos dirigidos a ácidos nucleicos de la proteína tau asociada a microtúbulos
ES2635595T3 (es) Un nuevo procedimiento para la purificación del activador tisular del plasminógeno
JP6525342B2 (ja) タグ付けされたｄｎａ断片の生成
WO2023220649A3 (en) Effector protein compositions and methods of use thereof
DE60210140D1 (de) Verfahren zur herstellung von polycarbonat
WO2023147240A2 (en) Variant type v crispr/cas effector polypeptides and methods of use thereof
AR042878A1 (es) Gen de enzima formadora de peptidos
WO2023220654A3 (en) Effector protein compositions and methods of use thereof